| Rationale for anti-OX40 cancer immunotherapy S Aspeslagh, S Postel-Vinay, S Rusakiewicz, JC Soria, L Zitvogel, ... European Journal of Cancer 52, 50-66, 2016 | 348 | 2016 |
| Combining epigenetic drugs with other therapies for solid tumours—past lessons and future promise D Morel, D Jeffery, S Aspeslagh, G Almouzni, S Postel-Vinay Nature Reviews Clinical Oncology 17 (2), 91-107, 2020 | 330 | 2020 |
| Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease FX Danlos, AL Voisin, V Dyevre, JM Michot, E Routier, L Taillade, ... European Journal of Cancer 91, 21-29, 2018 | 262 | 2018 |
| Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review JMK de Filette, JJ Pen, L Decoster, T Vissers, B Bravenboer, ... European journal of endocrinology 181 (3), 363-374, 2019 | 193 | 2019 |
| Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score) F Bigot, E Castanon, C Baldini, A Hollebecque, A Carmona, ... European Journal of Cancer 84, 212-218, 2017 | 160 | 2017 |
| Pharmacological sensitivity of ATP release triggered by photoliberation of inositol‐1, 4, 5‐trisphosphate and zero extracellular calcium in brain endothelial cells K Braet, S Aspeslagh, W Vandamme, K Willecke, PEM Martin, WH Evans, ... Journal of cellular physiology 197 (2), 205-213, 2003 | 148 | 2003 |
| Galactose‐modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis S Aspeslagh, Y Li, ED Yu, N Pauwels, M Trappeniers, E Girardi, T Decruy, ... The EMBO journal 30 (11), 2294-2305, 2011 | 133 | 2011 |
| Long-term survival in patients responding to anti–PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation ML Gauci, E Lanoy, S Champiat, C Caramella, S Ammari, S Aspeslagh, ... Clinical Cancer Research 25 (3), 946-956, 2019 | 125 | 2019 |
| Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies S Postel-Vinay, S Aspeslagh, E Lanoy, C Robert, JC Soria, A Marabelle Annals of Oncology 27 (2), 214-224, 2016 | 104 | 2016 |
| Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma CN Owen, X Bai, T Quah, SN Lo, C Allayous, S Callaghan, ... Annals of Oncology 32 (7), 917-925, 2021 | 84 | 2021 |
| Epigenetic modifiers as new immunomodulatory therapies in solid tumours S Aspeslagh, D Morel, JC Soria, S Postel-Vinay Annals of Oncology 29 (4), 812-824, 2018 | 81 | 2018 |
| Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study G Manson, ATJ Maria, F Poizeau, FX Danlos, M Kostine, S Brosseau, ... Journal for immunotherapy of cancer 7, 1-12, 2019 | 79 | 2019 |
| Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go? P De Bruyn, D Van Gestel, P Ost, V Kruse, L Brochez, H Van Vlierberghe, ... Current opinion in oncology 31 (2), 54-64, 2019 | 78 | 2019 |
| Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis E De Azambuja, M Brandão, H Wildiers, A Laenen, S Aspeslagh, ... ESMO open 5 (5), e000947, 2020 | 74 | 2020 |
| Immuno-oncology-101: overview of major concepts and translational perspectives B Allard, S Aspeslagh, S Garaud, FA Dupont, C Solinas, M Kok, B Routy, ... Seminars in cancer biology 52, 1-11, 2018 | 70 | 2018 |
| Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy S Le Burel, S Champiat, E Routier, S Aspeslagh, L Albiges, TA Szwebel, ... Annals of the Rheumatic Diseases, annrheumdis-2016-210820, 2017 | 70 | 2017 |
| Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer A De Meulenaere, T Vermassen, S Aspeslagh, P Deron, F Duprez, ... Oncotarget 8 (46), 80443, 2017 | 69 | 2017 |
| Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy L Dercle, S Ammari, S Champiat, C Massard, C Ferté, L Taihi, RD Seban, ... European journal of cancer 65, 33-42, 2016 | 65 | 2016 |
| TILs in head and neck cancer: ready for clinical implementation and why (not)? A De Meulenaere, T Vermassen, S Aspeslagh, K Vandecasteele, S Rottey, ... Head and neck pathology 11, 354-363, 2017 | 62 | 2017 |
| NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients S Rusakiewicz, A Perier, M Semeraro, JM Pitt, E Pogge von Strandmann, ... Oncoimmunology 6 (1), e1137418, 2017 | 54 | 2017 |
